Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Otulfi® ...

The first wave of Stelara (ustekinumab) biosimilars show steep Wholesale Acquisition Cost discounts greater than 80%, the report finds.

South Korea’s Samsung Bioepis today released its Second Quarter 2025 Biosimilar Market Report, which provides the second ...

Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street’s revenue expectations in Q1 CY2025, with ...

Learn more about whether Alvotech or Kymera Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, ...

Amgen AMGN will report first-quarter 2025 results on May 1, after market close. In the last reported quarter, the company ...

Thoughtworks, a global technology consultancy that integrates design, engineering and AI to drive digital innovation, today announced a three-year global Strategic Collaboration Agreement (SCA) with ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced ...

DoubleVerify ("DV") , the leading software platform for digital media measurement, data and analytics, today announced it is deepening its commitment to keeping digital advertising free from ...

including biosimilars of AstraZeneca/Alexion's Soliris (eculizumab), Amgen's Prolia (denosumab), and J&J's Stelara (ustekinumab). Biosimilars are near-copies of complex biologic drugs that have ...